ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ISPC / financials
BIAF (29) ONMD (26) MXCT (34) NRC (67) ⌘ Pro Terminal β†’

iSpecimen Inc. (ISPC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.83 +0.82% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

iSpecimen Inc. (ISPC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $2.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ISPC Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, iSpecimen Inc. (NASDAQ: ISPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.83 (+0.82% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ISPC ranks #817 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ISPC compare to BIAF and ONMD in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ISPC?
β–Ό

Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.83 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (30/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (9)Whales (3)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
$35 Bull$1 Base$1 Bear
πŸ“¬ FREE ISPC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ISPC)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
πŸ” WHY ISPC SCORES 30/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+9/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 11.2% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$1.08-11.1% Next Q
Q2 (-2Q)
35
Grade E$0.96-9.4% Next Q
Q3 (-1Q)
33
Grade E$0.87-4.6% Next Q
Current
30
Grade E$0.83-9.6% Hist 90D Ξ±
Trajectory: E (38) β†’ E (30)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ISPC Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ISPC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.87) forces dealer call-delta covering toward $34.61.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ISPCβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œISPC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How ISPC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.9MGross Profit $215.7K (11.2%)Cost of Sales $1.7MOp Profit $0 (0%)OpEx (R&D/SG&A) $215.7KNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $9.9M
FY24
Rev $9.3M
FY25
Rev $1.9M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$1.9M11.2%-80%-$10.5M-$4.2M-45%
FY 2024$9.3M45%-80%-$12.5M-$8.3M-45%
FY 2023$9.9M11.2%-80%-$11.1M-$5.8M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ISPC)

  • βœ“Walkthrough of ISPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ISPC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.63%⚑ TESTING RESISTANCE
2026-11-03O $0.80H $0.83L $0.80C $0.83VOL 543.3K
RES: $0.92SUP: $0.72SMA50: $1.20SMA200: $4.71
$26.37$19.42$12.48$5.54$-1.40RES $0.92SUP $0.72$0.832026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ISPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ISPC Butterfly Map β†’ + Track ISPC β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -79.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ISPC today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ISPC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ISPC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ISPC)

Health Care Rank #817 of 1015 βš”οΈ BIAF vs ISPC Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ISPC vs. BIAF, ONMD, MXCT, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, iSpecimen Inc. (ISPC) ranks #817 by composite RQD confidence (30/100, grade E) and #994 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and β€” gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ISPC at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ISPC ACTIVE
iSpecimen Inc.
E 30/100 β€” 11.2% -35.0% +0.82% $2.1M Benchmark Subject
BIAF
bioAffinity Technologies Inc.
E 29/100 β€” β€” -35.0% +2.75% $3.7M /biaf-vs-ispc β†’
ONMD
OneMedNet Corp (Class A)
E 26/100 β€” -30.0% -35.0% +1.42% $25.4M /onmd-vs-ispc β†’
MXCT
MaxCyte Inc.
E 34/100 β€” 96.0% -27.1% -8.80% $164.1M /mxct-vs-ispc β†’
NRC
NRC Health
C+ 67/100 44.8x β€” 21.0% +1.80% $527.1M /nrc-vs-ispc β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001558569 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), iSpecimen Inc. (ISPC) reported GAAP revenue of $1.9M (-79.2% vs. FY2024 revenue of $9.3M , and -80.6% cumulative change since FY2023) , GAAP net income of -$10.5M, operating cash flow of -$4.2M, and free cash flow of -$4.2M (+48.9% YoY). On the balance sheet, ISPC closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.9M -$10.5M -$4.2M -$4.2M $9.5M β€”
FY2024 (FY) 2024-12-31 $9.3M -$12.5M -$8.3M -$8.3M $9.4M β€”
FY2023 (FY) 2023-12-31 $9.9M -$11.1M -$5.8M -$5.8M β€” β€”

3. ISPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ISPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, iSpecimen Inc. (NASDAQ: ISPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.83 (+0.82% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ISPC ranks #817 in composite RQD confidence.

How does ISPC compare to BIAF and ONMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ISPC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 11.2%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ISPC?

Per ISPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001558569), iSpecimen Inc. generated $1.9M in revenue (-79.2% YoY), -$10.5M in net income, and -$4.2M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ISPC trading relative to its 50-day, 200-day, and 52-week technical levels?

ISPC last traded at $0.83 (+0.82% on volume of 108,488 shares), positioning the stock -30.83% below its 50-day simple moving average ($1.20) and -82.38% below its 200-day simple moving average ($4.71). Across its 52-week range of $0.75 to $32.96, ISPC sits at the 0.2% percentile with a 14-day RSI of 33.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.93).

Direct Sub-Reports: ISPC RQD Cockpit ISPC 12M Forecast ISPC Earnings & Move ISPC Dividends & DRIP ISPC Insiders & 13F ISPC Whale Options ISPC Profit Sankey ISPC News & Why
ROARABLE RATING BRIEF β€’ RQD 30/100 (E) βœ“ SEC XBRL & RQD VERIFIED

ISPC β€” iSpecimen Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

iSpecimen Inc. (ISPC) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.83 (+0.82% 1D, market capitalization $2.1M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 11.2%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ISpecimen Inc. (ISPC) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. Gross margin is reported at 11.2% per the market data section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), iSpecimen Inc. (ISPC) reported $1.9M in annual revenue (up from $9.3M in FY2024, -79.2% YoY) and -$10.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.9M revenue, -$11.1M net income) through FY2025, ISPC scaled operating cash flow to -$4.2M and free cash flow to -$4.2M, backed by $9.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.75 – $32.96 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Commercial Physical & Biological Resarch (Health Care), ISPC carries a macro regime beta of 1.00 and gross margin of 11.2%.

  • Key Question #1: Can ISPC sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.9M and free cash flow of -$4.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ISPC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ISPC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for iSpecimen Inc. (ISPC) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ISPC Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ISPC Bull vs. Bear Conversation Board β€” What's Your Call at $0.83?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ISPC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ISPC:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $1.10 (+32.5%)
πŸ“Œ Pinned Debate

Cash of $6.9M in FY 2025 exceeds that year's -$4.2M free cash flow outflow, per the SEC financials.

Long ISPC at $0.83 targeting $1.10. Cash of $6.9M in FY 2025 exceeds that year's -$4.2M free cash flow outflow, per the SEC financials.. Institutional whale score is 3/20 and the risk/reward vs. the $0.75 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 πŸ‚ BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Commercial Physical & Biological Resarch. If gross margin (11.2%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.71 (-14.5%)
Spot @ $0.83

Net income was negative in every reported period while revenue fell from $9.9M to $1.9M, per the SEC financials.

Fading this rally in ISPC at $0.83. Net income was negative in every reported period while revenue fell from $9.9M to $1.9M, per the SEC financials.. With a beta of 1.0 and the stock sitting at $0.83 (52-wk range $0.75–$32.96), the easy multiple expansion is already priced in.

LIVE TAPE